174 related articles for article (PubMed ID: 27986437)
21. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
Cox MC; Castiello L; Mattei M; Santodonato L; D'Agostino G; Muraro E; Martorelli D; Lapenta C; Di Napoli A; Di Landro F; Cangemi M; Pavan A; Castaldo P; Hohaus S; Donati S; Montefiore E; Berdini C; Carlei D; Monque DM; Ruco L; Prosperi D; Tafuri A; Spadaro F; Sestili P; Spada M; Dolcetti R; Santini SM; Rozera C; Aricò E; Capone I; Belardelli F
Clin Cancer Res; 2019 Sep; 25(17):5231-5241. PubMed ID: 31171545
[TBL] [Abstract][Full Text] [Related]
22. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
[TBL] [Abstract][Full Text] [Related]
23. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
[TBL] [Abstract][Full Text] [Related]
25. Intraventricular Rituximab in Pediatric CD20-positive Refractory Primary Central Nervous System Lymphoma.
Wada-Shimosato Y; Ikeda J; Tsujimoto SI; Sasaki K; Yanagimachi M; Kajiwara R; Shiba N; Murata H; Kawahara N; Yamanaka S; Tanoshima R; Ito S
J Pediatr Hematol Oncol; 2019 Oct; 41(7):571-573. PubMed ID: 30124546
[TBL] [Abstract][Full Text] [Related]
26. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.
Taverna C; Martinelli G; Hitz F; Mingrone W; Pabst T; Cevreska L; Del Giglio A; Vanazzi A; Laszlo D; Raats J; Rauch D; Vorobiof DA; Lohri A; Biaggi Rudolf C; Rondeau S; Rusterholz C; Heijnen IA; Zucca E; Ghielmini M
J Clin Oncol; 2016 Feb; 34(5):495-500. PubMed ID: 26712227
[TBL] [Abstract][Full Text] [Related]
27. Chlorambucil-rituximab as first-line therapy in patients affected by follicular non-Hodgkin's lymphoma: a retrospective single-centre study.
Martinelli G; Montoro J; Vanazzi A; Andreola G; Liptrott S; Radice D; Negri M; Preda L; Pruneri G; Laszlo D
Hematol Oncol; 2015 Dec; 33(4):129-35. PubMed ID: 25047267
[TBL] [Abstract][Full Text] [Related]
28. Conjunctival lymphoma in right eye: Case report.
Parada-Vásquez RH; Lomas-Guaman VE; León-Roldán CR
Arch Soc Esp Oftalmol; 2017 Feb; 92(2):78-81. PubMed ID: 27388111
[TBL] [Abstract][Full Text] [Related]
29. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
30. Chronic hepatitis E in patients with indolent lymphoma after treatment with rituximab and bendamustine.
Alnuaimi K; Lavolé J; Lascoux-Combes C; Roque Afonso AM; Sogni P; Pol S; Mallet V
Hepatology; 2018 Jun; 67(6):2468-2470. PubMed ID: 29194671
[No Abstract] [Full Text] [Related]
31. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
[TBL] [Abstract][Full Text] [Related]
32. Primary conjunctival follicular lymphoma treated with the anti-CD20 antibody rituximab and low-dose involved-field radiotherapy.
Takahira M; Okumura H; Minato H; Urushisaki N; Sakurai M; Sugiyama K
Jpn J Ophthalmol; 2007; 51(2):149-51. PubMed ID: 17401629
[No Abstract] [Full Text] [Related]
33. Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma.
Davies A; Trask P; Demeter J; Florschütz A; Hänel M; Kinoshita T; Pettengell R; Quach H; Robinson S; Sadullah S; Sancho JM; Udvardy M; Witzens-Harig M; Knapp A; Liu W
Ann Hematol; 2020 Dec; 99(12):2837-2846. PubMed ID: 32314038
[TBL] [Abstract][Full Text] [Related]
34. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
Moccia AA; Zucca E; Ghielmini M
Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.
Davies A; Merli F; Mihaljević B; Mercadal S; Siritanaratkul N; Solal-Céligny P; Boehnke A; Berge C; Genevray M; Zharkov A; Dixon M; Brewster M; Barrett M; MacDonald D
Lancet Haematol; 2017 Jun; 4(6):e272-e282. PubMed ID: 28476440
[TBL] [Abstract][Full Text] [Related]
36. Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies.
Milunović V; Bogeljić Patekar M; Jakubac KM; Mandac Rogulj I; Radić-Krišto D; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2017 Mar; 56(1):143-156. PubMed ID: 29120553
[TBL] [Abstract][Full Text] [Related]
37. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW
Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656
[TBL] [Abstract][Full Text] [Related]
38. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
Eberle FC; Holstein J; Scheu A; Fend F; Yazdi AS
J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
[TBL] [Abstract][Full Text] [Related]
39. Systemic remission of non-Hodgkin's lymphoma after intralesional interferon alpha-2b to bilateral conjunctival lymphomas.
Ross JJ; Tu KL; Damato BE
Am J Ophthalmol; 2004 Oct; 138(4):672-3. PubMed ID: 15488809
[TBL] [Abstract][Full Text] [Related]
40. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
